Application of ISG20 in prognosis and treatment of acute myelogenous leukemia
Through the detection and inhibition of ISG20, the difficulties in the assessment and treatment of AML prognosis recurrence risk assessment and treatment were solved, and AML cell proliferation inhibition and apoptosis delay were achieved, new AML therapeutic targets and drug compositions were provided, and the efficacy and survival of AML were improved. Rate.
Patent Information
- Application Number
- CN202411142063.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-20
- Publication Date
- 2024-11-26
AI Technical Summary
The prognostic recurrence risk of acute myeloid leukemia (AML), especially t(8; 21) type AML, is difficult to evaluate. The existing target treatment has problems of instability in expression and great toxicity, resulting in limited efficacy and immunosuppression of the tumor microenvironment. Making the treatment challenge huge.
Develop ISG20 as a new biomarker and target, and prepare diagnostic and prognostic evaluation kits by detecting ISG20 expression using transcriptome sequencing or PCR, and use ISG20 inhibitors such as shRNA to delay AML cell proliferation and apoptosis to prepare therapeutic compositions to inhibit ISG20 expression.
The correlation between high expression of ISG20 and AML recurrence and poor prognosis was verified. The proliferation and apoptosis of AML cells were delayed through ISG20 inhibitors, providing a new AML treatment direction and improving efficacy and survival rates.
Smart Images

Figure CN119020491A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of medical biotechnology, and relates to the application of ISG20 as a biomarker of acute myeloid leukemia (AML), especially t(8;21) type AML, and specifically relates to its application in evaluating the prognosis and treatment of t(8;21) type AML. Background Art
[0002] Acute myeloid leukemia (AML) is one of the most malignant hematopoietic diseases, accounting for 80% of acute leukemia in adults, and is characterized by the uncontrolled expansion of immature myeloid cells. Although the remission rate of AML patients after initial chemotherapy has improved with the development of medical technology, 20-70% of patients still relapse after achieving complete remission (CR), resulting in a five-year survival rate of less than 30% for AML patients. About half of AML patients are accompanied by non-random chromosomal translocations, including balanced translocations and abnormal chromosome numbers. The four most common translocations are 11q23 / mixed lineage leukemia (MLL)-fusion protein, t(15;17) / PML-RAR, Inv(16) / core binding factor (CBF)b-MYH11, and t(8;21) / RUNX1-RUNX1T1. The key molecular changes caused by these molecular events can promote tumor cell proliferation and anti-apoptosis, as well as AML transformation. In addition, although only 2% of newly diagnosed AML patients have extramedullary disease, up to 20% of AML patients experience extramedullary relapse after hematopoietic stem cell transplantation. Extramedullary metastasis of AML is mainly associated with the cytogenetic and molecular characteristics of leukemia and is associated with a poor prognosis.
[0003] It is worth noting that the tumor microenvironment (TME) plays a key role in the occurrence, development, proliferation and survival of AML cells. In the bone marrow and peripheral blood, the phenotypic and functional changes of various immune cells in the TME inhibit the anti-tumor immune response and enable tumor cells to escape immune surveillance. AML immunotherapy, such as bispecific T cell-binding antibodies, chimeric antigen receptor T cells or natural killer cell therapy, or checkpoint inhibitors are underway. Immunotherapy is conducive to the elimination of minimal residual lesions (MRD) in AML in order to achieve the deepest remission and prolong survival. There are currently several ongoing T cell immunotherapy targets for AML, including CD33, CD123, CLL-1, and CD70, but these targets present considerable challenges, such as unstable expression and high toxicity. Therefore, based on the unmet needs in the above AML treatment, the identification and development of AML-related tumor markers that can affect AML proliferation, overcome extramedullary metastasis, and improve the function of immune cells in the TME, and the development of corresponding targeted small molecule inhibitors, will help improve the efficacy of AML, restore patients' anti-tumor immunity, and ultimately prolong patient survival.
[0004] Interferon-stimulated exonuclease gene 20 (ISG20) is an interferon-stimulated protein located on human chromosome 15q26. It is also known as estrogen-regulated transcription 45 protein and is an RNA exonuclease induced by interferon (IFN type I and II) or double-stranded RNA. ISG20 can cut single-stranded RNA or DNA and is closely related to the host's antiviral innate immune defense. Multiple studies have shown that ISG20 is highly expressed in a variety of solid tumors and is involved in the occurrence and progression of tumors. For example, ISG20 is upregulated in cervical cancer and renal clear cell carcinoma; in gliomas, high expression of ISG20 indicates poor overall survival of patients; increased expression has also been reported in hematological tumors such as diffuse large B-cell lymphoma and leukemia, but no further mechanism has been explored.
[0005] The specific mechanism of how ISG20 affects the prognosis of cancer patients is still under exploration. Studies have found that ISG20 promotes the proliferation and metastasis of renal clear cell carcinoma by regulating the expression of CCND1 / MMP9; ISG20 with exonuclease activity enhances angiogenesis through the regulation of thyroid hormone and supports the progression of hepatocellular carcinoma (HCC). In addition to the impact on tumor proliferation and metastasis, in terms of the immune microenvironment, studies in human gliomas have found that high expression of ISG20 is associated with increased infiltration of monocyte-derived macrophages and neutrophils and inhibition of adaptive immune responses (Gao Mengqi et al., ISG20 promotes local tumor immunity and contributes to poor survival in human glioma, Oncoimmunology, 8(2): e1534038, 2019). The expression of ISG20 is also positively correlated with the expression of immune checkpoints and inhibitory receptors (PD-1, PD-L1, and CTLA4), which may be involved in the inhibition of immune cell function. Combined with the effects of ISG20 on tumor cells and the immune microenvironment, it is speculated that it can be explored as a potential therapeutic target in AML. Summary of the invention
[0006] The present invention is carried out on the basis of the above research and aims to provide new biomarkers and therapeutic targets for evaluating the risk of recurrence of AML prognosis.
[0007] The application team first conducted preliminary research on the RUNX1::RUNX1T1 target gene ISG20. In clinical studies, it was found that high expression of the interferon-stimulated gene ISG20 was significantly associated with patient relapse and poor prognosis. In addition, by collecting bone marrow mononuclear cell samples from normal people and patients with primary and recurrent AML for transcriptome sequencing (RNA-seq), it was found that ISG20 expression in patients with primary and recurrent AML was significantly higher than that in the normal group; at the same time, RNA-seq was performed by knocking down ISG20 in AML cells, and it was found that knocking down ISG20 could induce AML cell apoptosis and significantly inhibit its proliferation by regulating the cell cycle and TNF-α signaling pathway. Therefore, inhibiting ISG20 will help treat t(8;21) AML leukemia.
[0008] The first purpose of the present invention is to provide the use of ISG20 in the preparation of a t(8;21) type AML diagnosis and prognosis evaluation kit and a corresponding prognosis evaluation kit; the second purpose is to provide the use of an ISG20 inhibitor in the preparation of a pharmaceutical composition for treating t(8;21) type AML, and further provide a composition with the inhibitor as an active ingredient.
[0009] The specific technical solution adopted by the present invention is as follows:
[0010] In a first aspect, the present invention provides use of ISG20 in preparing a kit for diagnosis and prognosis evaluation of t(8;21) type AML.
[0011] Preferably, the kit comprises a reagent for detecting the expression of ISG20 in a biological sample. In the specific implementation of the present invention, the expression of ISG20 is detected by transcriptome sequencing (RNA-seq), so the kit provided by the present invention comprises a reagent for performing transcriptome sequencing (RNA-seq) on bone marrow mononuclear cells extracted from a biological sample.
[0012] Of course, ISG20 expression can also be detected by conventional PCR amplification. The primer sequences for qPCR amplification are as follows:
[0013] Forward sequence: TCTACGACACGTCCACTGACA (SEQ ID NO. 1);
[0014] Reverse sequence: CTGTTCTGGATGCTCTTGTGC (SEQ ID NO. 2);
[0015] Therefore, the kit of the present invention may also include PCR primers for specific detection of ISG20, and the primer sequences are shown in SEQ ID NOs. 1-2.
[0016] Further preferably, the biological sample of the present invention is selected from the patient's bone marrow tissue, from which bone marrow mononuclear cells can be extracted for transcriptome sequencing (RNA-seq), or RNA can be extracted and reverse transcribed for qPCR amplification.
[0017] In a second aspect, the present invention provides a t(8;21) type AML diagnosis and prognosis assessment kit, which comprises a reagent for detecting the expression level of ISG20 in a biological sample.
[0018] According to the above description, the reagent is preferably selected from a reagent for RNA-seq sequencing of bone marrow mononuclear cells extracted from a biological sample, or a PCR primer for specific detection of ISG20, and the primer sequence is shown in SEQ ID NO.1-2 above.
[0019] The third aspect of the present invention provides the use of an ISG20 inhibitor in the preparation of a pharmaceutical composition for treating t(8;21) type AML.
[0020] The ISG20 inhibitor may be selected from small molecule compounds that have an inhibitory effect on ISG20, agents that inhibit or silence the ISG20 gene, or agents that promote the metabolism of the ISG20 protein.
[0021] In the specific implementation of the present invention, ISG20 shRNA was used as an ISG20 inhibitor, and the results showed that it could delay the occurrence of leukemia in AML mice.
[0022] The nucleic acid sequence of the ISG20 shRNA is as follows:
[0023] shISG20_9938: GCAACGATGGAGCTCTATCAA (SEQ ID NO.3);
[0024] shISG20_9940: TGAGGGAGAGATCACCGATTA (SEQ ID NO. 4).
[0025] In a fourth aspect, the present invention provides a pharmaceutical composition for treating t(8;21) type AML, comprising an active component and a carrier, wherein the active component comprises the above-mentioned ISG20 inhibitor.
[0026] The beneficial protection and effects of the present invention are as follows:
[0027] The present invention verifies the high correlation between abnormally high expression of ISG20 and recurrence and poor prognosis of t(8;21) type AML through database analysis and combined analysis with clinical indicators, revealing that ISG20 can be used as a marker for the risk of recurrence of t(8;21) type AML. Further, through in vitro cell experiments and mouse models, it was verified that the expression of ISG20 can delay the occurrence of AE9a-driven leukemia. The research results of the present invention show that ISG20 is a risk marker for t(8;21) type AML and can be used as a target for AML treatment, providing a new direction for the treatment of AML. BRIEF DESCRIPTION OF THE DRAWINGS
[0028] Figure 1 The results showed that ISG20 was highly expressed in AML patient cells and significantly correlated with poor patient prognosis: A: expression of ISG20 after overexpression of RUNX1::RUNX1T1 in CD34+HSC cells; B: expression of ISG20 after knockdown of RUNX1::RUNX1T1 in kasumi-1 cells; C: expression of ISG20 in AML and normal subjects in the GEPIA database; D: expression of ISG20 in bone marrow mononuclear cells of 42 samples of newly diagnosed AML patients, 7 samples of relapsed AML and 24 normal subjects in our unit; E: expression of ISG20 in t(8;21) AML and normal subjects in the MILE database; F: relationship between ISG20 expression and prognosis in the GEPIA database; G: relationship between ISG20 expression and prognosis in the TCGA database.
[0029] Figure 2 The results showed that ISG20 knockdown resulted in blocked proliferation and increased apoptosis of AML cells: A: qPCR verified the effect of ISG20 knockdown in Kasumi-1 cells; B: CKK8 experiment observed the effect of ISG20 knockdown in Kasumi-1 cells on cell proliferation; C: Western Blot verified the effect of ISG20 knockdown in Kasumi-1 cells on AETFC complex; D: Flow cytometry observed the effect of ISG20 knockdown on apoptosis of Kasumi-1 cells; E and F: statistical results of Figure D.
[0030] Figure 3 It was shown that ISG20 knockdown inhibited the occurrence of leukemia in mice: A: qPCR verified the effect of ISG20 knockdown in AE9a cells; B: The effect of ISG20 knockdown on the pathogenesis of AE9a mouse model. DETAILED DESCRIPTION
[0031] The implementation of the present invention is described in detail below in conjunction with the embodiments of the present invention. The following embodiments are implemented on the premise of the technical solution of the present invention, and provide detailed implementation methods and specific operating processes, but the protection scope of the present invention is not limited to the following embodiments.
[0032] The experimental methods in the following examples, unless otherwise specified, are all conventional methods, and are performed according to the techniques or conditions described in the literature in the field or according to the product instructions. The materials, reagents, etc. used in the following examples, unless otherwise specified, can all be obtained from commercial channels.
[0033] ISG20 expression is significantly correlated with recurrence and prognosis of t(8;21) AML
[0034] By analyzing the CD34 + The data of overexpression of RUNX1::RUNX1T1 in HSC cells and knockdown of RUNX1::RUNX1T1 in kasumi-1 cells showed that the expression level of ISG20 was significantly increased when RUNX1::RUNX1T1 was overexpressed, and the expression level of ISG20 was significantly decreased after knockdown of RUNX1::RUNX1T1, indicating that ISG20 is a target gene of RUNX1::RUNX1T1 ( Figure 1 A and 1B).
[0035] In addition, GEPIA database analysis revealed that the expression of ISG20 in t(8;21) AML patient cells was significantly higher than that in normal subjects ( Figure 1 C and 1D), and high expression is associated with poor prognosis ( Figure 1 E and 1F), which indicates that it is feasible to treat AML by screening ISG20 small molecule inhibitors. In addition, we collected 42 samples of primary AML patients, 7 samples of relapsed AML and 24 normal human bone marrow mononuclear cells for RNA-seq sequencing and found that the expression of ISG20 in AML patients was slightly increased compared with normal controls, while the expression of ISG20 in relapsed AML patients was significantly higher than that in normal controls ( Figure 1 D).
[0036] 2. Knockdown of ISG20 induces apoptosis of AML cells and significantly inhibits cell proliferation
[0037] In order to clarify the role of ISG20 in t(8;21) leukemia, we infected t(8;21) AML cells with ISG20 shRNA (shISG20_9938 and shISG20_9940) plasmid packaging virus to study the effect of ISG20 knockdown on cell growth and proliferation in Kasumi-1 cells. Since the shRNA plasmid expresses a puromycin reporter gene downstream of the ISG20 short hairpin sequence as a marker, we selected puromycin to screen positive LSC cells 48h after infection with the ISG20 shRNA virus.
[0038] The results are as follows Figure 2 As shown in the figure, compared with the control group, the expression of ISG20 mRNA and protein levels in Kaumi-1 cells in the ISG20 shRNA knockdown group was significantly reduced, indicating that the ISG20 knockdown cell model constructed by shRNA has been successfully constructed (2A); CCK8 experiments showed that the proliferation efficiency of Kaumi-1 cells was significantly decreased after 48 hours of puromycin selection ( Figure 2 B); At the same time, flow cytometry analysis of apoptosis experiments showed that compared with the control group, the early apoptotic cells of Kaumi-1 cells in the ISG20 knockdown group (Annexin-V + PI - ) significantly increased ( Figure 2 D and 2E), late apoptosis (Annexin-V + PI + ) also increased significantly ( Figure 2 D and 2F).
[0039] 3. Knockdown of ISG20 inhibits the occurrence of leukemia in mice
[0040] AE9a cells come from Stephen D. Nimer's laboratory in the United States. The construction method is to transplant 14.5-day mouse fetal liver cells infected with MIGR1-haAE9a retrovirus into lethally irradiated recipient mice. After the mice become ill, spleen cells are removed and cultured with 1640 complete medium (10% FBS + 90% RPMI 1640 + PS) without cytokines. After multiple generations of culture, cytokine-independent AE9a cell lines are obtained. In this study, we used shRNA to knock down ISG20 in AE9a cells. The knockdown effect is as follows: Figure 3 As shown in A, the survival curve results showed that the onset of disease in the ISG20 knockdown group was significantly delayed compared with the control group (p = 0.0004) ( Figure 3 B), indicating that inhibition of ISG20 expression can delay AE9a-driven leukemogenesis.
[0041] The embodiments of the present invention have been specifically described above, but the present invention is not limited to the embodiments. Those skilled in the art may make various equivalent modifications or substitutions without violating the spirit of the present invention. These equivalent modifications or substitutions are all included in the scope defined by the claims of this application.
Claims
1. Use of ISG20 in the preparation of a diagnostic and prognostic evaluation kit for t(8;21) type AML.
2. The use according to claim 1, characterized in that The kit comprises a reagent for detecting the expression amount of ISG20 in a biological sample.
3. The use according to claim 1, characterized in that The reagent is selected from a reagent for genome sequencing of DNA extracted from a biological sample, or a PCR primer for specific detection of ISG20, and the primer sequence is shown in SEQ ID NO.1-2.
4. The use according to claim 1, characterized in that The biological sample is selected from patient bone marrow tissue.
5. A t(8;21) type AML diagnosis and prognosis assessment kit, characterized in that: Contains reagents for detecting the expression of ISG20 in biological samples.
6. The early assessment kit for obesity according to claim 5, characterized in that: in, The reagents include reagents for genome sequencing of DNA extracted from biological samples, or PCR primers for specific detection of ISG20, and the primer sequences are shown in SEQ ID NOs. 1-2.
7. Application of ISG20 inhibitors in the preparation of pharmaceutical compositions for the treatment of t(8;21) type AML.
8. The use according to claim 7, characterized in that: The inhibitor is selected from ISG20 shRNA, and the nucleic acid sequence is shown in SEQ ID NO. 3 and 4.
9. A pharmaceutical composition for treating t(8;21) type AML, characterized in that: It comprises an active component and a carrier, wherein the active component comprises the ISG20 inhibitor according to claim 7 or 8.
